BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 8808151)

  • 1. Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay.
    Wettstein JG; Grouhel A
    Pharmacol Biochem Behav; 1996 Feb; 53(2):411-6. PubMed ID: 8808151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo.
    Endoh T; Matsuura H; Tanaka C; Nagase H
    Arch Int Pharmacodyn Ther; 1992; 316():30-42. PubMed ID: 1326932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of the morphine-induced Straub tail reaction by kappa-opioid receptor activation in mice.
    Narita M; Suzuki T; Misawa M; Nagase H
    Psychopharmacology (Berl); 1993; 110(1-2):254-6. PubMed ID: 7870894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
    Paronis CA; Waddell AB; Holtzman SG
    Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats.
    Shannon HE; Lutz EA
    Neuropharmacology; 2002 Feb; 42(2):253-61. PubMed ID: 11804622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NMDA receptor antagonist MK-801 differentially modulates mu and kappa opioid actions in spinal cord in vitro.
    Feng J; Kendig JJ
    Pain; 1996 Aug; 66(2-3):343-9. PubMed ID: 8880858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of specific opioid agonists and antagonists to delineate the vagally mediated antinociceptive and cardiovascular effects of intravenous morphine.
    Randich A; Robertson JD; Willingham T
    Brain Res; 1993 Feb; 603(2):186-200. PubMed ID: 8096421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys.
    Ko MC; Willmont KJ; Lee H; Flory GS; Woods JH
    Brain Res; 2003 Aug; 982(1):38-44. PubMed ID: 12915238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay.
    Broadbear JH; Negus SS; Butelman ER; de Costa BR; Woods JH
    Psychopharmacology (Berl); 1994 Jul; 115(3):311-9. PubMed ID: 7871070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig.
    Culpepper-Morgan JA; Holt PR; LaRoche D; Kreek MJ
    Life Sci; 1995; 56(14):1187-92. PubMed ID: 7475895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats.
    Takemori AE; Schwartz MM; Portoghese PS
    J Pharmacol Exp Ther; 1988 Dec; 247(3):971-4. PubMed ID: 2849679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys.
    Butelman ER; Negus SS; Ai Y; de Costa BR; Woods JH
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1269-76. PubMed ID: 8263790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum.
    Gray AC; White PJ; Coupar IM
    Br J Pharmacol; 2005 Mar; 144(5):687-94. PubMed ID: 15678085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
    Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys.
    Ko MC; Lee H; Song MS; Sobczyk-Kojiro K; Mosberg HI; Kishioka S; Woods JH; Naughton NN
    J Pharmacol Exp Ther; 2003 Apr; 305(1):173-9. PubMed ID: 12649366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinociceptive effects of morphine and U-50,488H on vaginal distension in the anesthetized rat.
    Friese N; Diop L; Lambert C; Rivière PJ; Dahl SG
    Life Sci; 1997; 61(16):1559-70. PubMed ID: 9353165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Place aversion induced by blockade of mu or activation of kappa opioid receptors in the dorsal periaqueductal gray matter.
    Sante AB; Nobre MJ; Brandão ML
    Behav Pharmacol; 2000 Nov; 11(7-8):583-9. PubMed ID: 11198129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.